Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 4(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04974151Phase 4Recruiting

China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype

Role: lead

NCT04974138Phase 4Recruiting

China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)

Role: lead

NCT03472508Phase 4Unknown

H-Type Hypertension Precision Medicine Trial

Role: lead

NCT01871740Phase 4Withdrawn

CSPPT- Chronic Kidney Diseases Study

Role: lead

NCT00794885Phase 4Completed

China Stroke Primary Prevention Trial

Role: lead

NCT01956786Phase 2Unknown

Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Role: lead

NCT01848873Phase 2Unknown

Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Role: lead

All 7 trials loaded